Quarterly report pursuant to Section 13 or 15(d)

Significant Accounting Policies - Disaggregation of Revenue (Details)

v3.10.0.1
Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Disaggregation of Revenue [Line Items]        
Total revenue $ 4,785,138 $ 157,800 $ 9,267,913 $ 542,006
Prescribed dietary supplements        
Disaggregation of Revenue [Line Items]        
Total revenue 1,925,543 0 3,669,791 0
Prescription drugs        
Disaggregation of Revenue [Line Items]        
Total revenue 2,785,376 0 5,301,247 0
Sales force revenue        
Disaggregation of Revenue [Line Items]        
Total revenue 74,219 0 296,875 0
Grant revenue        
Disaggregation of Revenue [Line Items]        
Total revenue $ 0 $ 157,800 $ 0 $ 542,006